Cannabis Patients with Advanced Bile Duct Cancer Survived Nearly 7x Longer Than Standard Care Alone
In a Thai retrospective study, advanced cholangiocarcinoma patients receiving medical cannabis survived a median of 5.7 months versus 0.8 months with standard palliative care — a dramatic difference that warrants cautious interpretation.
Quick Facts
What This Study Found
Cholangiocarcinoma (bile duct cancer) is devastating in Northeast Thailand, where incidence is among the highest in the world due to endemic liver fluke infections. Most patients are diagnosed at advanced stages with poor prognoses and very short survival times.
This retrospective study compared 491 newly diagnosed advanced cholangiocarcinoma patients across six hospitals: 404 received standard palliative pain management and 87 received medicinal cannabis treatment (Thailand was the first Southeast Asian country to legalize medical cannabis). The results were dramatic.
Median survival for the standard treatment group was 0.83 months (about 25 days). For the cannabis treatment group, median survival was 5.66 months — nearly seven times longer. The mortality rate was 48.35 per 100 person-months in the standard group versus 10.9 per 100 person-months in the cannabis group.
These numbers are eye-catching, but they demand careful interpretation. This was a retrospective study, not a randomized trial. Patients who received cannabis treatment may have been systematically different from those who didn't — perhaps healthier at baseline, more engaged with their care, or diagnosed earlier despite being classified as 'advanced.' Selection bias is a major concern. The survival difference is also far larger than what's been seen in any cannabis-cancer study, which raises questions about confounding factors rather than confirming a direct cannabis anti-tumor effect.
Key Numbers
491 patients total: 404 standard care, 87 cannabis treatment. Standard care median survival: 0.83 months (95% CI: 0.71–0.95). Cannabis group median survival: 5.66 months. Standard care mortality rate: 48.35/100 person-months. Cannabis group mortality rate: 10.9/100 person-months. Total follow-up: 790 person-months (standard) and 476 person-months (cannabis).
How They Did This
Retrospective cohort study comparing survival among 491 newly diagnosed advanced cholangiocarcinoma patients from six hospitals in Northeast Thailand (September 2019–June 2021). The cannabis group (87 patients) received medical cannabis treatment; the standard group (404 patients) received conventional palliative pain management. Survival was calculated using Kaplan-Meier methods, and prognostic factors were analyzed using Cox regression.
Why This Research Matters
Cancer survival claims for cannabis are among the most emotionally charged topics in cannabis research. This study shows a real survival difference in real patients, but the retrospective design means we can't conclude cannabis caused the difference. What this study does well is document that medical cannabis can be integrated into palliative cancer care in a Southeast Asian healthcare setting, and that the survival difference is large enough to justify the randomized controlled trials needed to establish causation.
The Bigger Picture
This study is important to contextualize carefully. The cannabis-and-cancer research space is full of in vitro studies showing cannabinoids can kill cancer cells in a dish, but very few human studies showing meaningful clinical outcomes. This retrospective study shows a provocative survival signal, but it's the kind of finding that generates hypotheses rather than proving them. Randomized trials are essential before drawing any treatment conclusions.
What This Study Doesn't Tell Us
Retrospective design with no randomization — selection bias is the primary concern. Patients who sought out cannabis treatment may have been systematically healthier, more motivated, or had better access to healthcare. The standard care group's median survival of 0.83 months is extremely short, suggesting these patients may have been at a more advanced disease stage. No blinding was possible. Cannabis dosing and formulations were not standardized. Cultural and regional factors in Thailand may limit generalizability to other populations.
Questions This Raises
- ?Would a randomized controlled trial replicate this dramatic survival difference?
- ?Were the two groups truly comparable in disease stage and baseline health?
- ?Is the survival benefit driven by cannabis anti-tumor effects, better symptom management (leading to better nutrition and function), or selection bias?
- ?Can these findings be generalized beyond the specific epidemiology of cholangiocarcinoma in Thailand?
Trust & Context
- Key Stat:
- Evidence Grade:
- This is a retrospective cohort study with a large sample but no randomization. The dramatic survival difference is attention-grabbing but highly susceptible to selection bias, making it hypothesis-generating rather than conclusive.
- Study Age:
- Published in 2022, based on patients treated 2019–2021 during the early phase of Thailand's medical cannabis program.
- Original Title:
- Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.
- Published In:
- F1000Research, 11, 1212 (2022) — F1000Research is a reputable open-access journal known for publishing high-quality research across various fields.
- Authors:
- Phansila, Narisara, Pansila, Paopong, Wongkongdech, Adisorn, Turnbull, Niruwan, Azam, Mahalul, Wongkongdech, Ranee
- Database ID:
- RTHC-04147
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04147APA
Phansila, Narisara; Pansila, Paopong; Wongkongdech, Adisorn; Turnbull, Niruwan; Azam, Mahalul; Wongkongdech, Ranee. (2022). Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.. F1000Research, 11, 1212. https://doi.org/10.12688/f1000research.123250.3
MLA
Phansila, Narisara, et al. "Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.." F1000Research, 2022. https://doi.org/10.12688/f1000research.123250.3
RethinkTHC
RethinkTHC Research Database. "Survival rate of patients with combined hepatocellular chola..." RTHC-04147. Retrieved from https://rethinkthc.com/research/phansila-2022-survival-rate-of-patients
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.